Solving solubility problems is one of the leading challenges in drug development, as poorly soluble compounds are estimated to account for 60% of compounds. Preclinical development encompasses the activities that link the drug discovery process in the lab to initiation of human clinical trials. Anuj Kuldipkumar, PhD, Scientist II at Vertex Pharmaceuticals, identifies steps to take in developing toxicology and safety studies to identify potential target organs for
adverse effects.
You may be interested in this podcast: Steps to Expediting time-to-market for Insoluble Drug Candidates
|
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |